Last updated: November 11, 2026
Prexasertib, Eli Lilly’s intravenous checkpoint kinase 1 inhibitor, has no FDA approval, no commercial sales, and no established launch date. Public development has centered on recurrent ovarian cancer, triple-negative breast cancer, and other advanced solid tumors. The clinical profile showed antitumor activity, but severe hematologic toxicity, intravenous administration, and the absence of a validated biomarker have limited commercial prospects. The base-case market projection is $0 through the near term unless a sponsor restarts development and generates positive randomized data.
What is the current development status of prexasertib?
Prexasertib, also known as LY2606368, is a selective small-molecule CHK1 inhibitor administered by intravenous infusion. CHK1 regulates DNA-damage response and cell-cycle progression. Inhibition is intended to increase replication stress and drive tumor-cell death, particularly in tumors with defective DNA-repair pathways.
Eli Lilly has been the principal developer. Prexasertib has not reached a registrational Phase 3 program or an FDA filing based on the public clinical record.
| Attribute |
Prexasertib status |
| Generic name |
Prexasertib |
| Development code |
LY2606368 |
| Drug class |
Selective CHK1 inhibitor |
| Modality |
Small molecule |
| Administration |
Intravenous |
| Lead developer |
Eli Lilly and Company |
| FDA approval |
None |
| Commercial status |
Not marketed |
| Orange Book listing |
None |
| Confirmed launch date |
None |
| Principal clinical focus |
Recurrent ovarian cancer and advanced solid tumors |
| Main development risk |
Myelosuppression, especially neutropenia |
Clinical studies have evaluated prexasertib as monotherapy and in combinations with DNA-damaging agents. Publicly reported work has included recurrent BRCA-wild-type high-grade serous ovarian cancer, triple-negative breast cancer, pediatric solid tumors, and other refractory malignancies. ClinicalTrials.gov records indicate that several studies have been completed, terminated, or otherwise lack evidence of progression toward registration. [1]
What clinical data support prexasertib?
The strongest efficacy signal came from a Phase 2 study in recurrent BRCA-wild-type high-grade serous ovarian cancer. The study evaluated prexasertib in patients with heavily pretreated disease, including patients whose tumors lacked BRCA mutations.
Published results reported an objective response rate of approximately 29% in the evaluable population, with responses observed despite extensive prior treatment. Median progression-free survival was approximately four months. The activity was clinically relevant for a population with limited options, but the study was small, single-arm, and insufficient to establish comparative benefit. [2]
Key ovarian-cancer data
| Metric |
Reported result |
| Disease setting |
Recurrent BRCA-wild-type high-grade serous ovarian cancer |
| Study type |
Phase 2, single-arm |
| Objective response rate |
Approximately 29% |
| Median progression-free survival |
Approximately 3.7 months |
| Key safety issue |
Grade 3/4 neutropenia |
| Route |
Intravenous |
The response signal did not establish that CHK1 inhibition improves overall survival or progression-free survival compared with approved therapies. The development case also faced competition from poly(ADP-ribose) polymerase inhibitors, antibody-drug conjugates, platinum rechallenge, and other targeted therapies.
In triple-negative breast cancer, prexasertib was investigated because the disease often has high replication stress and limited targeted treatment options. Available public data have not shown a clinical benefit sufficient to support a regulatory filing. The same limitation applies to other exploratory tumor types.
How strong is the prexasertib clinical profile?
Prexasertib has a credible biological mechanism and demonstrated monotherapy activity. Its clinical profile is weaker as a commercial asset because the efficacy evidence is derived mainly from early-stage, nonrandomized studies.
Positive development factors
- Activity was reported in heavily pretreated ovarian cancer.
- The mechanism is relevant to tumors with replication stress and DNA-repair defects.
- Responses were reported in BRCA-wild-type disease, where treatment options remain differentiated from BRCA-directed strategies.
- CHK1 inhibition could potentially be combined with chemotherapy, PARP inhibitors, or other DNA-damage therapies.
Negative development factors
- Neutropenia was frequent and clinically significant.
- Intravenous dosing creates a higher treatment burden than oral targeted therapies.
- No predictive biomarker has been clinically validated.
- The evidence has not demonstrated superiority or a durable benefit against modern standards of care.
- Combination strategies may increase overlapping marrow toxicity.
- The program has not produced a late-stage registration path.
The central development question is whether a biomarker-selected population can produce a sufficiently large therapeutic window. Without that evidence, prexasertib competes as an intravenously administered cytotoxic-like targeted agent in a market increasingly favoring oral drugs, antibody-drug conjugates, and biomarker-defined therapies.
What is the FDA regulatory status of prexasertib?
Prexasertib is not FDA-approved and has no established FDA exclusivity period. It does not have a New Drug Application approval, a Biologics License Application, or an approved indication listed by FDA.
The drug has no approved-label status under the Federal Food, Drug, and Cosmetic Act. There is no public basis to assign a Prescription Drug User Fee Act action date or a commercial launch window.
Orange Book status
Prexasertib is not listed as an FDA-approved drug product in the Orange Book. As a result:
- There is no Orange Book-listed patent for an approved prexasertib product.
- There is no Orange Book reference-listed drug.
- Abbreviated New Drug Application applicants cannot file Paragraph IV certifications against a marketed prexasertib product.
- No approved-product patent litigation framework currently applies.
Clinical-trial patents or pending patent applications may exist, but they do not create FDA Orange Book protection unless associated with an approved product and listed under FDA rules. [3]
When does prexasertib lose exclusivity?
Prexasertib has no FDA-granted market exclusivity because it has not been approved. Any patent protection must be analyzed separately by patent family, jurisdiction, claim scope, terminal disclaimers, patent-term adjustment, and maintenance status.
Public clinical development materials identify prexasertib as LY2606368, but the commercial value of any composition-of-matter or method-of-use patents is limited by the absence of an approved product and the apparent lack of active late-stage development.
| Exclusivity category |
Status |
| FDA approval |
None |
| New chemical entity exclusivity |
Not granted |
| Orphan-drug exclusivity |
No established approved indication |
| Pediatric exclusivity |
None established |
| Orange Book patent term |
None |
| Paragraph IV exposure |
No current approved-product pathway |
| Commercial exclusivity |
None |
A patent expiry date cannot be treated as a launch date. Even if a patent family remains in force, a generic or other developer would still need an approved product, clinical support, manufacturing capability, and a viable regulatory pathway.
What patents protect prexasertib?
Prexasertib’s patent position likely includes research-era patent families covering CHK1 inhibitors, pharmaceutical compositions, and therapeutic uses. The existence of those families does not establish that a particular patent claims prexasertib specifically, remains enforceable, or would block a competing CHK1 inhibitor.
A complete patent assessment would require current records from the USPTO, WIPO, EPO, and national registers, including continuations, divisionals, assignments, prosecution history, patent-term adjustment, and maintenance fees. The available regulatory record does not provide a reliable, consolidated expiration table for prexasertib-specific claims.
Likely protection categories
- Compound and salt claims
- Pharmaceutical composition claims
- Intravenous formulation claims
- Methods of treating ovarian cancer
- Methods involving BRCA-wild-type tumors
- Combination treatment with DNA-damaging agents
- Dosing schedules intended to manage neutropenia
- Biomarker-defined patient-selection methods
The most commercially important claims would be valid composition-of-matter claims and enforceable method-of-use claims covering a defined patient population. Formulation and dosing claims would have less value if competitors could use a different formulation, schedule, or route.
Are there Paragraph IV challenges or generic competitors?
No meaningful Paragraph IV challenge has been established because prexasertib lacks an approved reference product and Orange Book listing. There are also no known commercial generic versions.
A future generic challenge would be unlikely unless Lilly or another sponsor first obtained approval. If the compound-of-matter patent had expired by that point, a generic developer could pursue a conventional abbreviated pathway, subject to any remaining formulation or method-of-use patents. If method-of-use claims remained active, a label carve-out could become relevant.
The more realistic competitive threat is not a traditional generic. It is substitution by other DNA-damage-response therapies, including PARP inhibitors, ATR inhibitors, WEE1 inhibitors, platinum agents, and antibody-drug conjugates.
What patent litigation affects prexasertib?
No major public patent litigation involving an approved prexasertib product is established. There is no known Hatch-Waxman litigation record tied to a commercial prexasertib reference product.
Clinical-trial disputes, patent-prosecution disputes, or licensing matters involving CHK1 technology would not automatically affect market entry. The practical litigation risk would rise only if a sponsor revived the program, obtained approval, and listed enforceable patents in the Orange Book.
What is the market projection for prexasertib?
The base-case forecast is no revenue through the near term because prexasertib has no approval, no launch plan, and no visible late-stage program. A commercial forecast based on historical clinical activity alone would overstate its value.
| Scenario |
Development outcome |
Near-term revenue outlook |
| Base case |
Program remains inactive or discontinued |
$0 |
| Re-entry case |
Sponsor restarts Phase 2 with biomarker strategy |
No meaningful revenue before approval |
| Positive registration case |
Phase 3 success and FDA approval in ovarian cancer |
Potential specialty-oncology product |
| Broad-label case |
Approval expands into breast and other solid tumors |
Higher upside, but low probability |
A successful relaunch would require several steps:
- Identify a predictive biomarker, such as replication-stress or DNA-repair deficiency markers.
- Select a disease setting with measurable unmet need.
- Establish a tolerable dosing schedule.
- Demonstrate benefit against current standard therapy.
- Resolve intravenous administration and treatment-center burden.
- Secure sufficient intellectual-property protection for the approved use and formulation.
Potential commercial opportunity if revived
The most plausible initial market would be recurrent ovarian cancer, particularly patients with platinum-resistant or BRCA-wild-type high-grade serous disease. That market is clinically meaningful but crowded. A successful product would likely need a differentiated response rate, durable disease control, or a combination benefit that justifies its hematologic toxicity.
The product would face competition from:
- PARP inhibitors, where patients remain eligible
- Mirvetuximab soravtansine in folate-receptor-alpha-positive ovarian cancer
- Platinum-based chemotherapy
- Weekly paclitaxel
- Topotecan
- Pegylated liposomal doxorubicin
- Other antibody-drug conjugates and DNA-damage-response inhibitors
An approval restricted to a biomarker-defined subgroup could support premium pricing but would limit the addressable population. A broad label would increase revenue potential but require stronger efficacy and safety evidence.
How does prexasertib compare with other CHK1 and DNA-damage-response drugs?
Prexasertib entered a field in which several agents target replication stress, but the competitive standard has moved toward oral dosing and biomarker selection.
| Drug or class |
Target |
Development/commercial position |
Relative issue for prexasertib |
| Prexasertib |
CHK1 |
Unapproved clinical candidate |
Requires development restart and stronger validation |
| Adavosertib |
WEE1 |
Clinical development |
Similar replication-stress rationale; oral administration may be advantageous |
| Ceralasertib |
ATR |
Clinical development |
Competes for DNA-damage-response positioning |
| Olaparib and other PARP inhibitors |
PARP1/2 |
Approved in multiple settings |
Established efficacy and oral dosing |
| Mirvetuximab soravtansine |
FR-alpha-directed ADC |
Approved in ovarian cancer |
Direct competition in a relevant disease population |
| Platinum chemotherapy |
DNA crosslinking |
Established standard |
Lower novelty but familiar clinical use |
Prexasertib’s differentiation depends on activity in tumors that are resistant to PARP inhibitors and platinum therapy. That is a difficult population because resistance frequently reflects broader DNA-repair adaptation and aggressive disease biology.
What licensing deals involve prexasertib?
Eli Lilly is the publicly identified principal developer. No major out-licensing transaction or commercial co-development agreement has established a current partner with responsibility for prexasertib commercialization.
The absence of a visible licensing transaction is consistent with a program whose commercial value remains unproven. A future deal would likely be structured around a development restart, biomarker rights, or a combination program rather than immediate commercial rights.
What generic launch risks exist for prexasertib?
A conventional generic launch risk is currently low because there is no approved product. If development resumes, risk would shift to patent and regulatory timing.
The main scenarios are:
- A sponsor obtains approval while composition patents remain active, delaying generic entry.
- Composition claims expire, but formulation or use patents remain enforceable.
- A competitor develops a different CHK1 inhibitor and avoids prexasertib claims.
- A generic files after patent expiry but faces limited demand because the market has moved to competing targeted therapies.
- A label carve-out permits use outside patented indications.
The commercial risk is therefore more closely tied to clinical obsolescence than to immediate generic substitution.
Key Takeaways
- Prexasertib is an unapproved intravenous CHK1 inhibitor developed primarily by Eli Lilly.
- The strongest reported signal was an approximately 29% response rate in a small Phase 2 ovarian-cancer study.
- Severe neutropenia and the lack of a validated biomarker are major liabilities.
- There is no FDA approval, Orange Book listing, Paragraph IV litigation, or commercial revenue.
- No reliable launch date or active late-stage registration program is established.
- The base-case market projection is $0 in the near term.
- A viable relaunch would require biomarker selection, improved tolerability, and randomized evidence against modern ovarian-cancer therapies.
- Competitive pressure comes from PARP inhibitors, antibody-drug conjugates, platinum agents, ATR inhibitors, and WEE1 inhibitors.
FAQs
Is prexasertib still being developed?
Public clinical evidence does not establish an active late-stage development program. The asset remains an unapproved clinical candidate without a confirmed commercial sponsor or launch timeline.
Has prexasertib been approved for ovarian cancer?
No. FDA has not approved prexasertib for ovarian cancer or any other indication.
Is prexasertib an oral drug?
No. Clinical studies have evaluated prexasertib as an intravenous treatment.
Can a generic company launch prexasertib now?
No commercial generic launch pathway is currently available because there is no FDA-approved prexasertib reference product.
What would increase the value of prexasertib?
The strongest value drivers would be a validated biomarker, reduced neutropenia, durable responses in platinum- and PARP-resistant ovarian cancer, and positive randomized data supporting a registrational filing.
References
-
ClinicalTrials.gov. (n.d.). Studies involving prexasertib (LY2606368). U.S. National Library of Medicine. https://clinicaltrials.gov/
-
Lee, J. M., et al. (2018). Prexasertib in BRCA wild-type recurrent high-grade serous ovarian cancer: A single-arm phase 2 study. The Lancet Oncology.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Eli Lilly and Company. (2024). Annual report. https://investor.lilly.com/financial-information/annual-reports-and-proxy-statements
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/